Sarepta Therapeutics said early Tuesday that a patient had died after receiving its gene therapy Elevidys, which treats the ...

Opens in a new tab or window A young person with Duchenne muscular dystrophy died following treatment with the recently approved gene therapy ... The patient died after experiencing acute liver ...

A few weeks after Sarepta Therapeutics confirmed a patient died after receiving its drug Elevidys, research published April 3 ...

Shares of Sarepta, based in Cambridge, Massachusetts, dropped more than 27% on Tuesday, closing at about $73 per share. Elevidys, which costs $3.2 million for a one-time infusion, was the first gene ...

Sarepta Therapeutics said Tuesday that a 16-year-old boy died after receiving Elevidys, its gene therapy ... noted that over 800 patients have now been treated with the therapy.

Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy. The patient ...

The patient, a young man, suffered acute liver failure after receiving the therapy ... death. Fatalities have also been reported following the launch of Novartis’s Zolgensma, an AAV-delivered ...

The death of a young boy with Duchenne muscular dystrophy (DMD) who was treated with Pfizer’s experimental gene therapy in a phase 2 trial has prompted the company to pause dosing in another study.

A patient has died while receiving Elevidys, a gene therapy for Duchenne muscular dystrophy, marking the first known death linked to the treatment. The company behind the drug, Sarepta ...